How Medicare Blocks Access to Lifesaving Treatments

Why It Matters

Lifting the CED restriction could dramatically increase treatment rates for a life‑threatening condition, improving outcomes for an aging population and setting a precedent for Medicare’s handling of innovative therapies.

Key Takeaways

• Medicare's CED policy restricts TAVR coverage for seniors
• Only 31% of eligible U.S. patients received TAVR under CED
• June decision could lift CED, expanding access to minimally invasive valve replacement
• Early TAVR treatment reduces death, stroke, and hospitalizations per NEJM study
• Advocacy groups urge Congress to end CED restrictions on Medicare

Pulse Analysis

The Coverage with Evidence Development (CED) framework was introduced in 2005 as a utilization‑management tool, allowing Medicare to reimburse new technologies only when patients participate in limited studies. In practice, CED has become a gatekeeper for high‑impact innovations such as transcatheter aortic valve replacement (TAVR), a catheter‑based procedure that avoids open‑heart surgery. By tying reimbursement to narrow registries and specific provider qualifications, the policy has left millions of seniors with severe aortic stenosis waiting for care, despite FDA approval and professional‑society endorsement of TAVR as the preferred treatment for most patients.

Clinical evidence now challenges the rationale for continued CED restrictions. A 2024 New England Journal of Medicine study demonstrated that asymptomatic patients receiving TAVR early experienced significantly lower rates of death, stroke, and unplanned cardiovascular hospitalizations compared with watchful‑waiting strategies. The FDA’s May 2025 approval to treat asymptomatic aortic stenosis further underscores the shift toward proactive intervention. These data suggest that the benefits of early TAVR extend beyond individual outcomes, potentially reducing overall healthcare costs by preventing expensive emergency admissions and long‑term complications.

The pending June decision carries weight far beyond valve disease. If Medicare removes the CED requirement for TAVR, it would signal a broader willingness to streamline access to breakthrough therapies, pressuring private insurers to follow suit. Patient‑advocacy groups such as Heart Valve Voice‑US and WomenHeart have mobilized lawmakers, citing legal opinions that label CED as inconsistent with Medicare’s statutory authority. A policy reversal could catalyze legislative action to eliminate CED across other high‑cost, high‑value treatments, reshaping the landscape of Medicare innovation adoption and improving equity in care delivery.